Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Blood · 02.11.2023 · 142 (18) · 1518-1528
DOI: 10.1182/blood.2022019531 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Blood, erschienen am 02.11.2023. Verfasst von Laura Rosiñol und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic de Barcelona, Insitut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
From November 2014 to May 2017, 332 patients homogeneously treated with bortezomib, lenalidomide, and dexamethasone (VRD) induction, autologous stem cell transplant, and VRD consolidation were randomly assigned to receive maintenance therapy with lenalidomide and dexamethasone (RD; 161 patients) vs RD plus ixazomib (IRD; 171 patients). RD consisted of lenalidomide 15 mg/d from days 1 to 21 plus dexamethasone 20 mg/d on days 1 to 4 and 9 to 12 at 4-week intervals, whereas in the IRD arm, oral ixazomib at a dose of 4 mg on days 1, 8, and 15 was added. Therapy for patients with negative measurable residual disease (MRD) after 24 cycles was discontinued, whereas those who tested positive for MRD remained on maintenance with RD for 36 more cycles. After a median follow-up of 69 months from the initiation of maintenance, the progression-free survival (PFS) was similar in both arms, with a 6-year PFS rate of 61.3% and 55.6% for RD and IRD, respectively (hazard ratio, 1.136; 95% confidence interval, 0.809-1.603). After 2 years of maintenance, treatment was discontinued in 163 patients with negative MRD, whereas 63 patients with positive MRD continued with RD therapy. Maintenance discontinuation in patients tested negative for MRD resulted in a low progression rate (17.2% at 4 years), even in patients with high-risk features. In summary, our results show the efficacy of RD maintenance and support the safety of maintenance therapy discontinuation in patients with negative MRD at 2 years. This trial was registered at www.clinicaltrials.gov as #NCT02406144 and at EudraCT as 2014-00055410.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Clinic de Barcelona, Insitut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
- Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain.
- Hematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
- Hematology Department, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cancer, Valencia, Spain.
- Hematology Department, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain.
ORCID-Profile: Laura Rosiñol, Albert Oriol, Rafael Ríos, Isidro Jarque, Miguel Teodoro Hernández, Valentín Cabañas, Anna Sureda, Joaquín Martínez-López, Isabel Krsnik, Maria Esther González, Luis Felipe Casado, Antonia Sampol, Yolanda González-Montes, Bruno Paiva, Noemí Puig, María-Victoria Mateos, Jesús San Miguel, Juan José Lahuerta
Zitieren
APA
Rosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo-Cruz, E., Sureda, A., Martínez-López, J., Krsnik, I., González, M. E., Casado, L. F., Martí, J. M., Encinas, C., de Arriba, F., Palomera, L., Sampol, A., …, & Bladé, J. (2023). Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood, 142(18), 1518-1528. https://doi.org/10.1182/blood.2022019531
Vancouver
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518-1528. doi:10.1182/blood.2022019531
BibTeX
@article{Rosiol2023,
author = {Rosiñol, Laura and Oriol, Albert and Ríos, Rafael and Blanchard, María Jesús and Jarque, Isidro and Bargay, Joan and Hernández, Miguel Teodoro and Cabañas, Valentín and Carrillo-Cruz, Estrella and Sureda, Anna and Martínez-López, Joaquín and Krsnik, Isabel and González, Maria Esther and Casado, Luis Felipe and Martí, Josep María and Encinas, Cristina and de Arriba, Felipe and Palomera, Luis and Sampol, Antonia and González-Montes, Yolanda and Cabezudo, Elena and Paiva, Bruno and Puig, Noemí and Cedena, María Teresa and de la Cruz, Javier and Mateos, María-Victoria and San Miguel, Jesús and Lahuerta, Juan José and Bladé, Joan},
title = {Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma},
journal = {Blood},
year = {2023},
volume = {142},
number = {18},
pages = {1518--1528},
doi = {10.1182/blood.2022019531}
}
EUVIMED